The presentations mention 40 patients received CF33 applications but only the 2 bile duct results are highlighted. That's a problem for many. If they can promote the bile duct data, why not the other data too? Even YF only referred to the bile duct outcome. From the slide one can only conclude that all the other cancer types had not seen any " meaningful " response. And that could be one reason why neither investors nor pharma are excited. Yes, the FDA is paving the way for Bile Duct for IMU but it is not the FDA's job to determine whether a treatment will become commercially a success or not. They look at efficacy and safety. If those criteria are met they approve but if big pharmas' criteria aren't met any FDA approval will be worthless. And that's the way it looks atm.
No deal, no funds. Same at CHM and look how the current cap raising has "supported" CHM. A similar scenario is highly likely here too.
It seemed too good to be true. Sadly, the bubble has burst.
No transparency, just more uncertainty. And that is fueling the selling. Wished I would have realised that much sooner but lived for too long in the LC and TB world.
IMU Price at posting:
3.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)